Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Pegylated liposomal-doxorubicin + ZN-c3|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pegylated liposomal-doxorubicin||Doxil||ATI-0918|CAELYX||Chemotherapy - Anthracycline 11||Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|ZN-c3||ZNc3|ZN c3||WEE1 Inhibitor 5||ZN-c3 is a small molecular inhibitor of WEE1 and inhibition of WEE1 increases DNA damage in cancer cells to induce programmed cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04516447||Phase I||Pegylated liposomal-doxorubicin + ZN-c3 Carboplatin + ZN-c3||A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer||Recruiting||USA||6|